Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. The company is headquartered in San Diego, California and currently employs 177 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The firm's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. The company is headquartered in San Diego, California and currently employs 177 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The firm's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).
Revenue Decline: Q3 revenue was $17.2 million, down $24.5 million from last year, mainly due to lower COVID vaccine collaboration income.
Lower Expenses: Operating expenses fell significantly to $33.7 million from $52.4 million last year, driven by reduced manufacturing, clinical, and payroll costs.
Cystic Fibrosis Progress: The ARCT-032 program showed encouraging early results in reducing mucus burden; a 15 mg dose cohort is ongoing with 12-week study planned for 2026.
COVID Vaccine Shift: US KOSTAIVE filing delayed indefinitely due to FDA changes and uncertain commercial prospects; focus shifts to commercialization in Asia and Europe.
Cash Runway Extended: Cash position of $237.3 million at quarter end and cost reductions extend runway into 2028.
OTC Program Advancing: Positive ARCT-810 data; regulatory meetings on pivotal trial design are expected in first half of 2026.
Expense Outlook: General and administrative expenses are expected to decrease slightly in fiscal 2026.
